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Allosteric sodium binding cavity in 
GPR3: a novel player in modulation 
of Aβ production
Stefano Capaldi  1, Eda Suku1, Martina Antolini2, Mattia Di Giacobbe2, Alejandro Giorgetti1,3 
& Mario Buffelli2
The orphan G-protein coupled receptor 3 (GPR3) belongs to class A G-protein coupled receptors (GPCRs) 
and is highly expressed in central nervous system neurons. Among other functions, it is likely associated 
with neuron differentiation and maturation. Recently, GPR3 has also been linked to the production of 
Aβ peptides in neurons. Unfortunately, the lack of experimental structural information for this receptor 
hampers a deep characterization of its function. Here, using an in-silico and in-vitro combined approach, 
we describe, for the first time, structural characteristics of GPR3 receptor underlying its function: the 
agonist binding site and the allosteric sodium binding cavity. We identified and validated by alanine-
scanning mutagenesis the role of three functionally relevant residues: Cys2676.55, Phe1203.36 and Asp2.50. 
The latter, when mutated into alanine, completely abolished the constitutive and agonist-stimulated 
adenylate cyclase activity of GPR3 receptor by disrupting its sodium binding cavity. Interestingly, this is 
correlated with a decrease in Aβ production in a model cell line. Taken together, these results suggest an 
important role of the allosteric sodium binding site for GPR3 activity and open a possible avenue for the 
modulation of Aβ production in the Alzheimer’s Disease.
G-protein coupled receptors (GPCRs) are the largest and the most heterogeneous group of proteins in the eukar-
yotic genome1,2. They consist of seven transmembrane alpha-helices that span the entire width of the membrane 
with the N-terminus positioned outside the cell and the C-terminus located in the cytosol. These receptors receive 
messages from the extracellular environment and, through conformational changes, they codify and transmit 
these messages inside the cell, activating several intracellular pathways. These activations affect the production of 
hundreds of second messenger molecules as Ca+ and cyclic AMP (cAMP)3.
The life-cycle of a GPCR can be summarized in four states: ligand binding, G protein coupling, receptor 
desensitization through the interaction with β-arrestins, and receptor recycling4,5. Since this process is very com-
plex and involves a tremendous variety of signaling molecules, GPCRs are the target of a large number of pharma-
ceutical compounds. In fact, between 20–30% of FDA-approved medications target GPCRs6. The most prominent 
therapeutic applications involving GPCRs include opioid analgesics, antihistamines, anticholinergics, typical and 
atypical antipsychotics, antimigraine drugs, b2-agonists for asthma, and anti-hypertensives7.
Misregulation of GPCRs activity is known to be implicated in the onset and progression of many different 
pathologies, including many types of cancers, cardiovascular diseases, metabolic disorders, and neurodegenera-
tive diseases8,9. Among these, Alzheimer’s disease (AD) has the most increasing trend in incidence and mortality. 
AD is a progressive neurodegenerative disorder and, accounting for 50 to 70% of the cases, it is the most common 
form of dementia10,11. It is estimated to affect more than 45 million people worldwide (5.5 million only in the 
US) as a result of global population aging12–14. The early symptoms of AD usually appear in the sixth decade of 
life and include cognitive deficit, apathy, and short-term memory loss15–18. Although the etiology of AD is still 
unclear, the accumulation and deposition of amyloid beta peptide (Aβ) fibrils in the intracellular and extracellular 
space are recognized as key events for the neuronal damage and synaptic failure in AD patients19,20. The two most 
abundant amyloidogenic Aβ peptides (1–40 and 1–42) are generated from the sequential cleavage of the large 
Amyloid-β precursor Protein (APP) by β-secretase (or BACE1) and γ-secretase complex21–25. The β-secretases 
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and γ-secretases play a fundamental role in amyloid precursor protein (APP) proteolysis and Aβ generation and 
are therefore regarded as the two major targets in AD drug discovery.
Recently, a high-throughput functional genomics screening, identified the G-protein coupled receptor 3 
(GPR3) as a potent modulator of the APP processing26. GPR3, an orphan class A GPCR, is highly expressed in 
central nervous system (CNS) neurons, where it was associated to neuron differentiation and maturation27,28, 
and in ovary and testes, where it is involved in the maintenance of meiotic arrest in oocytes29. GPR3 acts as con-
stitutive activator of adenylyl cyclase30,31 and its physiological ligand, if exists, is still unknown. Several endog-
enous molecules, including sphingosine 1-phosphate (SP1) and dihydrosphingosine 1-phosphate (DHSP1), 
have been proposed as potential ligands for GPR3 but with contrasting results32,33. More recently a synthetic 
molecule, diphenyleneiodonium chloride (DPI), has been reported to act as a GPR3 agonist, increasing the 
GPR3-stimulated cAMP production and the receptor desensitization and internalization34. Overexpression of 
GPR3 in APP-processing cells significantly increases the production of both Aβ 1–40 and Aβ 1–42 by enhancing 
γ-secretase activity with a mechanism that promotes the assembly and the trafficking of its components to the cell 
membrane. Moreover, GPR3-deficient mice exhibit lower accumulation of Aβ peptides26. In a subsequent work, 
the effect of the receptor on Aβ production has been ascribed to its ability to directly interact with APP, and the 
formation of this complex seems to be mediated by the recruitment and binding of β-arrestin 2 (βarr2) to GPR335. 
All these studies, however, are devoid of a complete structural analysis of the binding cavity, giving only experi-
mental information on ligands affinity.
Recent progress in GPCRs crystallography opened an unprecedented avenue for receptor-ligand characteriza-
tion. Nevertheless, the lack of structural data for about the 95% of the members of the family36, including GPR3, 
calls upon the development of specific pipelines in which, GPCRs-targeting in silico tools are combined with 
extensive in vitro experiments.
Using computational tools, we were able to model the structure of the GPR3 and perform docking and molec-
ular dynamics simulations with its known agonist, DPI. Based on the computational predictions, we identified 
three key residues and, together with our in vitro experiments, described the effect of their mutations on constitu-
tive and ligand-stimulated activity of the receptor and on the GPR3-induced production of Aβ in model cell line. 
One of these mutants turned out to completely abolish the signal of the receptor, acting as an inverse agonist, with 
the consequence of decreasing the production of Aβ. Thus, our results could provide an initial starting point for a 
specific drug design pipeline of the GPR3 receptor.
Results and Discussion
Homology modeling and molecular dynamics simulations. GPR3 is a fascinating GPCR receptor 
both from a structural and functional point of view. It is known to be involved in many molecular pathways, from 
modulating the early phases of cocaine reinforcement37 to the maintenance of meiotic arrest in rodent oocytes30 
and emotional-like responses38. Very recently it was discovered to play a fundamental role in modulating the 
amyloid-beta peptide generation in neurons through the interaction with βarr226. The finding that certain G 
protein–coupled receptors (GPCRs), including also the β2-adrenergic receptor in addition to the GPR3, can 
regulate Aβ production39 has offered new avenues for Alzheimer’s drug discovery. In fact, whereas genetic abla-
tion of GPR3 reduced Aβ levels, the overexpression of the latter increased Aβ production in Alzheimer’s mouse 
model26. The fact that GPR3 could be the key to find new treatments for the Alzheimer’s Disease, makes this 
receptor an ideal case of study especially from a structural point of view. Unfortunately, the GPR3 receptor does 
have neither a known 3D structure nor a known endogenous agonist. Only a study on its constitutive activity has 
been reported40 for this receptor as well as some data on two non-endogenous ligands: (i) an agonist, DPI34 and 
(ii) an inverse agonist, cannabidiol41. Although the latter has been recently associated to GPR3, it is not specific 
for this receptor as it interacts also with a close homolog, GPR6. Thus, here the model of the GPR3 receptor was 
built based on the active structure of human A2a adenosine receptor (PDB code: 5G53)42, using the GOMoDo 
webserver43. The GPR3 receptor shared ~23% of sequence identity with the template and this value was within 
the range of the identities between the target and its best templates. However, this template turned out to be the 
most reasonable in terms of MODELLER scores44 and its conformational active state45, which is expected to be 
suitable for the agonist-bound state studies (see Methods). The target-template alignment was then manually 
checked in order to verify the presence of ALL the conserved features of the GPCRs family as the X.50 in each 
transmembrane helix, the DRY motif in transmembrane helix 3 and the NPxxY motif in transmembrane helix 
746. All the conserved features were preserved (SI1) except for the disulfide bridge between the extracellular loop 
2 (ECL2) and transmembrane helix 3 (TM3). Indeed, GPR3 has no cysteines in the TM3 (see Methods and SI1 
for alignment details).
The generated model was then used to perform in silico docking experiments using the Haddock program47 
through the GOMoDo webserver. The residues located in the top half part of the receptor (SI2) were predicted 
as located in the putative binding cavity and used as ambiguous interaction restraints (AIR) for the docking step 
(see Methods). Once the last docking step was completed, all the complexes (200 in total) were clustered. The 
best docking GPR3-DPI pose (Fig. 1) was chosen as the one with the lowest HADDOCK score within the most 
populated cluster. In that conformation, the synthetic agonist DPI is positioned inside the canonical GPCRs 
orthostatic cavity48 (Fig. 1A). GPR3’s putative binding cavity results mostly hydrophobic, with the phenyl rings of 
DPI interacting with Leu2837.39, Leu1133.32, Trp2606.48, and Val186ECL2 (Fig. 1B). Among all the interactions, two 
specific interactions captured our attention, (i) a halogen-bond interaction49 between the iodine atom of DPI and 
Cys2676.55 (~4 Å) and (ii) a ‘sandwich-like’ conformation in which DPI is inserted between two phenylalanine 
residues, Phe1203.36 and Phe2636.51 (Fig. 1C).
Nonetheless, due to the low sequence identity and with the aim of better sample the conformational space of 
the ligand within the putative binding cavity50–53, the best complex was funneled to perform molecular dynam-
ics (MD) simulations using a hybrid molecular mechanics/coarse-grained (MM/CG) approach in order to 
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exhaustively explore the conformational space of the ligand, the binding cavity, and the hydration shell (SI3) 
as in54,55. A detailed description of the MM/CG can be found in the SI section: MM/CG technique description.
The system underwent 700 nanoseconds (ns) of simulations at room temperature, reaching the stability after 
300 ns (SI4 and SI5). We then clustered all the trajectory and analyzed the representative conformation of the most 
populated cluster (Fig. 2A). We noticed very few differences comparing the docking and the simulations results. 
The simulations relaxed and did not alter the receptor/DPI interactions compared with the initial conformation 
(Fig. 2B, red color and green color). Indeed, during the simulations, DPI slightly shifted and tilted from its initial 
position, assuming a non-planar conformation, maintaining however the interaction with Cys2676.55 which side 
chain moved towards to the iodine atom at distance <4 Å. Simulations thus confirmed the halogen-bond interac-
tion predicted by docking experiments. Moreover, also other two residues involved in the docking predictions, 
Phe1203.36 and Phe2636.51 confirmed their contribution in the ligand binding, shifting the side chains accordingly 
the DPI rings position (Fig. 2B, green color) and maintaining the π-stacking interactions with the ligand.
Furthermore, we decided to study also the putative sodium (Na+) allosteric binding site, that has a fundamen-
tal importance in allosteric modulation of GPCRs50,51. The residues that mostly contribute to sodium binding 
along the GPCRs family, i.e S3.39, N7.45 and D2.50 are described in literature as highly conserved. In particular, we 
observed that residue in position 2.50 (Fig. 1D) is an aspartic acid in 90% of the eukaryotic GPCRs accordingly 
to the curated multiple sequence alignment of the GPCRdb. This residue can highly modulate the function of 
GPCRs. The role of sodium modulation is well known for GPCRs51. Mutagenesis studies on residues involved 
in Na+ coordination, and in particular Asp2.50, highlighted the different effects that allosteric sodium may have 
in various class A GPCRs signaling50. Indeed, Asp2.50 replacement with uncharged amino acids can drastically 
reduce the agonist-induced G protein activation56–61 or modulate the allosteric effect of the G-protein on ligand 
binding62. The presence of sodium ions in the allosteric cavity can also exert different effects on the constitutive 
signaling of GPCRs. In many cases, the presence of bound Na+ seems to stabilize the inactive conformation of the 
receptor reducing the constitutive G-protein58–60, whereas in other receptors the substitution of Na+ coordinating 
Asp250 abolishes the constitutive G-protein coupling and activation without affecting the agonist-stimulated activ-
ity63. Exhaustive studies have also revealed that the Na+ pocket collapses due to the activation-related movements 
of the transmembrane helixes64,65. In the allosteric binding site, Na+ is coordinated by a salt bridge formed with 
Asp2.50 together with other additional polar interactions with Ser3.39 and Asn7.49. Most of the studies agree with the 
fact that the constitutive activity can be dramatically affected by mutations in Asp2.50 66–68.
Figure 1. GPR3-DPI complex docking results. In all the panels the GPR3 receptor is shown in salmon and its 
agonist DPI is shown in cyan. Residues side chains located in the orthosteric binding cavity are shown in cyan, 
while residues located in the sodium allosteric binding cavity are shown in red. The receptor is oriented with 
the N-terminus in the extracellular part and the C-terminus in the intracellular part (A), DPI and side chains 
of residues 5 Å distant from the agonist are shown in cyan (B), chemical structure of DPI with the iodine atom 
indicated in violet (C), side chains of residues involved in allosteric sodium binding are shown in red (D).
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In the light of these results together with the results obtained with our simulations, we decided to proceed with 
in vitro experiments to validate/reject our hypothesis.
Effect of selected single point mutations on GPR3 signaling. We performed wet-lab alanine scan-
ning mutagenesis on residues Cys2676.55 and Phe1203.36 (SI6), putatively involved in halogen and π-stacking inter-
actions with the ligand, respectively, and on D862.50, the highly conserved acidic residue present in the putative 
allosteric Na+ binding site. The three mutants were first tested for expression and localization in eukaryotic cells. 
Figure 3 shows representative immunofluorescence confocal images of HEK293 (A) and H4swe (B) cells express-
ing GPR3 wild type and D86A, F120A and C267A mutants. In all the cases, the receptor is clearly distinguishable 
in the cells, with no appreciable difference in fluorescence intensity and distribution between the WT protein and 
the three mutants. These results indicate that the mutations of these residues do not hamper the expression nor 
the correct folding and trafficking of the receptor in the cells.
Thus, we investigated the effect of the three mutations on the constitutive and DPI-induced activation of 
GPR3. Figure 4 displays dose-response curves obtained measuring the cAMP concentration in HEK293 cells 
transfected with WT or mutant receptors and treated with increasing concentration of DPI. The deletion of 
Cys2676.55 or Phe1203.36 side chains, predicted by in silico experiments to be involved in DPI binding, has the 
effect to increase the DPI EC50 from ~2 µM in GPR3 WT to 5 µM and 15 µM, respectively. This can be explained 
by a decreased affinity for the agonist due to a reduction of molecular contacts in the binding cavity when mutants 
are introduced, and further supports the accuracy of our model. Indeed, we performed also an in silico docking 
between the mutated receptor and the DPI and we noticed a reduction in the number of complexes in the most 
populated cluster (SI7), hampering the choice of one single structure as the representative of the most populated 
cluster. Indeed, the number of clusters increased and the number of structures within the clusters reduced signif-
icantly, thus no clear solution is offered.
Conversely to the previous two mutants, the mutation in alanine of Asp862.50, putatively involved in the 
allosteric Na+ binding site completely abolished either the constitutive and DPI-induced stimulation of adenylyl 
cyclase by GPR3, suggesting that this mutation produces a totally inactive form of the receptor. These results point 
out that binding of allosteric Na+ is essential for GPR3 to maintain its constitutive activity or to assume an active 
conformation.
Next, we investigated the effect of constitutive and agonist-induced activity of our mutants on βarr2 interac-
tion. β-arrestin proteins are ubiquitous modulators of GPCRs signaling that recognize and bind to specific phos-
phorylated residues in the C-terminal tail of active GPCRs and antagonize the interaction with the G-protein. 
This promotes the desensitization and the internalization of the receptor. HEK293 cells transfected with the WT 
receptor or three mutants were treated 30 minutes with DMSO (vehicle control) or 50 μM DPI and the amount 
of intracellular cAMP was determined. Compared with the empty vector control, the constitutive activity of the 
WT receptor results in a 3-fold increase in cAMP level in unstimulated cells, whereas the expression of F120A 
Figure 2. Molecular dynamics results of DPI located in the GPR3 orthosteric binding cavity. DPI-GPR3 
complex, together with the water dome that surrounds the The MM and CG regions of the receptors are shown 
in cyan and blue colors, respectively. The receptor is oriented with the N-terminus in the extracellular part and 
the C-terminus in the intracellular part. In the top right part the best docking complex is shown. While DPI 
located in the orthosteric binding cavity of the GPR3 receptor is shown in red,  residues Cys6.55, F3.36 and 
F6.51  are shown in cyan. In the bottom right, MM/CG simulations of the best complex is represented. DPI is 
shown in green, while Cys6.55, F3.36 and F6.51 residues are shown in cyan.
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Figure 3. Expression and subcellular localization of WT GPR3 and mutants. Representative confocal images of 
HEK 293 (A) and H4swe (B) cells expressing wild-type (WT) or single point mutants of GPR3. Cells were fixed 
with 4% paraformaldehyde 24 hours post transfection and stained with a monoclonal antibody against the Myc 
epitope fused to the C-terminal end of the receptor. The nuclei were stained with DAPI (blue). Single Z-planes 
(right panels) and maximum intensity projections (Z-stack, left panels) are shown for each sample.
Figure 4. Effect of single point mutations on DPI-induced activation of GPR3. Dose-response curves for DPI in 
HEK293 cells expressing WT and single point mutants of GPR3. Twenty four hours after transfection, cells were 
stimulated for 30 minutes with increasing concentration of DPI and the intracellular cAMP level was measured. 
cAMP values were normalized to the maximal response. Nonlinear regression analysis was performed to 
generate dose-response curves and calculate concentration for 50% of the maximal effect (EC50). Data are the 
mean ± SD of 3 independent experiments.
www.nature.com/scientificreports/
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and C267A mutants produces a lower, but still significant, increase of cAMP (Fig. 5A, black bars). Upon DPI 
stimulation, an up to 10-fold increment in cAMP concentration is observed for the WT receptor and 5 to 6-fold 
for F120A and C267A (Fig. 5A, red bars). Again, neither constitutive nor DPI-induced activity is detected for 
D86A mutant. When the same experiment is conducted in presence of co-expressed βarr2 (Fig. 5B), a sensi-
ble decrease in constitutive activity of WT, F120A and C267A mutants is observed, while no considerable 
effect can be detected for control and D86A mutated receptor. DPI stimulation still produces an increase in the 
cAMP level compared to the control (except for D86A mutant), but remarkably lower than in absence of βarr2. 
These findings suggest that, like WT GPR3, activated F120A and C267A mutants are negatively modulated by 
βarr2-mediated desensitization, whereas D86A, being totally inactive and therefore likely not-phosphorylated by 
G protein-coupled receptor kinases (GRKs), is probably unable to interact with βarr2 and this does not allow to 
appreciate any modulating effect. D68A mutant, although retaining proper folding and localization, appears to be 
completely unable to stimulate adenylate cyclase both in constitutive conditions and upon agonist stimulation. In 
this view, the presence of the highly conserved negatively charged Asp250, and consequently a complete and func-
tional allosteric Na+ binding pocket, seems to be essential for this receptor to maintain its constitutive activity 
and to activate Gs-protein for downstream signaling. The unraveling of the functional role of the sodium ion in 
the activation of GPR3 certainly deserves a deeper investigation.
GPR3-stimulated Aβ production is correlated with receptor activation. One of the most interest-
ing features of GPR3 is its implication in the APP processing and Aβ amyloid secretion. The first evidence of its 
role in the amyloid beta production process has been reported for the first time in 200926, where the authors high-
lighted its ability to up-regulate the γ-secretase activity and Aβ accumulation in neuronal cultures and in animal 
models. Subsequent works demonstrated that GPR3 modulation of APP cleavage is independent by G-protein 
coupling but is rather correlated to the recruitment and interaction of the receptor with βarr269. Therefore, we 
investigated the correlation between the modulating effects of our mutants on GPR3 activity and the stimulated 
production of Aβ peptides. H4swe cells, expressing the Swedish mutation (K595N/M596L) of amyloid precursor 
protein (APP-swe), were transfected with WT or mutated GPR3 (alone or in presence of co-transfected βarr2) 
and the amount of Aβ 1–42 released in the culture medium was measured by ELISA 24 hours after transfection 
(Fig. 6A). As expected, a statistically relevant (p < 0.05) increment of Aβ with respect to the control is observed 
for WT GPR3, F120A and C267A, while the inactive mutant D86A does not significantly increase the amount of 
secreted amyloid peptide. When βarr2 is co-expressed with the receptor (cyan bars), the picture is less clear. βarr2 
induces a slight increment in the Aβ 1–42 level in the control (probably modulating other signaling pathways in 
the cells) but does not affect significantly the amount of peptide produced in cells transfected with WT recep-
tor or mutants. As a result, we could not detect any statistically relevant effect of βarr2 on GPR3 in this cellular 
model. To further assess the correlation between the activation of GPR3 and its ability to enhance the production 
of Aβ, we performed the same experiment in presence of an agonist. Due to the lack of knowledge regarding its 
physiological ligand we used DPI, the only known compound able to activate GPR3. Due to DPI poor selectivity 
(e.g. it is known to strongly inhibit nitric oxide synthetase from macrophages and endothelial cells and other 
Figure 5. βarr2 decreases constitutive and DPI-induced activity of GPR3. (A) HEK293 cells transfected with 
empty vector (pcDNA3.1), WT GPR3 and single point mutants were treated with DMSO or 50 μM DPI for 
30 minutes and the intracellular cAMP level was measured. (B) The same experiment as in A was performed 
in presence of co-transfected human βarr2. 10 μM Forskolin, a known adenylate cyclase activator, was used as 
a positive control. Data are the mean ± SD of four independent experiments. cAMP values were normalized 
to the control (empty vector untreated). Statistical significance was determined by one-way ANOVA with 
Bonferroni-Holmes post-hoc test comparing all samples with the relative control (empty vector) (*p < 0.05, 
**p < 0.01).
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flavoenzymes) and cell toxicity, even at micromolar concentration, DPI does not have any potential therapeutic 
application, but it is a useful experimental tool in studying GPR3 signaling in vitro. In this case, the transfected 
cells were incubated 24 hours with 1 μM DPI (a prolonged exposure to higher concentration of DPI resulted in 
higher cell toxicity, Figure SI8) and the amount of Aβ 1–42 was quantified as before (Fig. 6B). Compared to the 
empty vector control, DPI stimulation produces a ~50% increase in the amyloid peptide level for WT and, to a 
less extent, for F120A and C267A, whilst had no influence on D86A. Again, co-transfection with βarr2 produces 
no appreciable difference in the production of Aβ promoted by WT GPR3 or mutants and the control in these 
cell line. Taken together, our results prompt us to suggest that there is a correlation between the permanence of 
the receptor in the active state and its modulation role on γ-secretase complex, although this process has been 
reported to be independent of G-protein activation. Indeed, DPI stimulation proportionally increases Aβ pro-
duction in WT and agonist-sensitive mutants, while D86A mutant, devoid of any cAMP stimulation activity and 
unable to gain access to the active state, is also ineffective in stimulating the production of amyloid peptides. Once 
activated, GPCRs are phosphorylated at specific positions by GPR kinases that specifically recognize the active 
form of the receptor and this modification considerably increase the recruitment and binding of β-arrestins. In 
this view, although indirectly, our findings further support the hypothesis of the involvement of β-arrestin medi-
ated desensitization/internalization pathway in GPR3 modulation of Aβ secretion.
Conclusions
In this work, we built the first homology model of GPR3 and performed combined docking/molecular dynamics 
simulations to investigate structural features of this receptor and its binding site. The predictive power of our 
model allowed the characterization of the GPR3 binding cavity with detailed analysis of GPR3 interaction with 
DPI and of the Na+ binding site, unraveling unexpected effects of the Asp2.50 mutation on GPR3 activity and Aβ 
production. These results brought the light on new possible targets for AD, paving the way for prevention and new 
therapeutic interventions in Alzheimer’s disease.
Methods
Homology modeling. The crystal structure of the GPR3 receptor is not available yet, thus homology mode-
ling technique was carried out to predict its 3D structure. The sequence was retrieved from the Uniprot database 
(Uniprot entry: P46089) and the model was generated through the GOMoDo web-server, as in52,53,70,71. First, 
a multiple sequence alignment was generated by the GOMoDo webserver to create a Hidden Markov Model 
(HMM) for our target. The resulting HMM of the GPR3 target were aligned against all the HMMs of the GPCR 
templates available in the GOMoDo webserver, using HHsearch 2.0.16 algorithm66. The use of profile-profile 
HMMs alignments is known to improve the target-template alignment especially if the latter has a low sequence 
identity69, ~23%, as in our case. Then 100 models were generated for each target-template pair using MODELLER 
9v1072. MODELLER quality scores were used to evaluate the receptor models based on DOPE (lower better) 
and GA341 (higher better) values73,74. Among all the templates, the human A2A adenosine receptor (PDB code: 
5G53, resolution: 2.79 Å) was identified as the most suitable one (see also Results section). On one hand, the 
models generated with A2A adenosine receptor as template showed better MODELLER quality scores73,74 for all 
the hChem-GPCRs object of this study. On the other, this template was solved in a fully active state45,46, which 
is expected to be the agonist-bound conformational state. The template-target alignment was then checked by 
hand, in order to preserve the conserved features of class A GPCRs (SI1). We use the GPCRdb generic number 
Figure 6. D86A mutation reduces the GPR3-stimulated Aβ production in H4swe cells. H4swe cells transfected 
with empty vector (pcDNA3.1), WT GPR3 and single point mutants, either in absence (blue bars) or in 
presence (cyan bars) of co-transfected human βarr2, were treated with DMSO (A) or 1 μM DPI (B) for 24 hours 
and the amount of Aβ 1–42 in the culture medium was determined by ELISA. Data are the mean ± SD of three 
independent experiments. Statistical significance was determined by one-way ANOVA with Bonferroni-Holmes 
post-hoc test comparing all samples with the relative control (empty vector) (*p < 0.05).
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position36 to have a coherent numeration of the residues between the target and the template. The chosen model 
was further considered for docking.
Docking Experiments. The agonist DPI, was docked on the final GPR3 receptor model using the 
HADDOCK v2.147 pipeline through the GOMoDO webserver43. Since the GPR3 has never been characterized 
at a binding level, first the putative binding cavity residues (SI2) were predicted using the Fpocket server75. Then, 
these residues, that covered the top half part of the protein, were used as active residues to guide the docking 
experiments. The structure of DPI was manually designed using the MarviSketch tool (http://www.chemaxon.
com) and was initially parametrized using the PRODRG server76. After we noticed that the partial charges were 
wrongly attributed, we parametrize again the ligand with ACPYPE (ACPYPE - AnteChamber PYthon Parser 
interface) and manually changed the partial charges in the PRODRG files (see SI9 and SI10). 1000 random struc-
tures were generated through the first initial rigid docking step. Then, after an initial ranking, the best 200 com-
plexes underwent through the refinement step with both ligand and receptor treated as flexible. The resulting 
receptor-agonist complexes were clustered using an RMSD cutoff of 1.0 Å and the complex of the most populated 
cluster with the lowest HADDOCK score underwent 700 ns of molecular mechanics/coarse-grained MM/CG 
molecular dynamics simulations54,55.
Molecular Dynamics Simulations. The complex was divided into two parts i) a MM part, which includes 
the extracellular region of GPR3, agonist and the residues in the binding cavity and ii) a CG part, containing 
the lower half part of the protein55. Since GPR3 is a membrane receptor the presence of the lipid bilayer in our 
case was taken into account introducing a wall located at 2.0 Å from the protein’s Cα atoms. The MM region was 
described with the GROMOS 96 force field, water was described with the SPC force field and the CG part was 
described using a Go-like potential as in52–55. In order to keep fixed the distance of bonds containing hydrogen(s) 
we used the SHAKE algorithm. The simulations were performed at a constant temperature (300K). Once com-
pleted the simulation, a clustering analysis was performed. For this purpose, all the protein backbone was aligned, 
and all the conformations were clustered according to the position of the ligand. A 1 Å cut-off was used to group 
different frames in the same cluster as in52–55.
DNA Constructs. The complete GPR3 sequence was isolated from a human blood sample containing leuco-
cytic DNA. The sequence, amplified by PCR, was TA-cloned into the pGEM-T Easy Vector and sequence-verified. 
For mammalian expression, GPR3 was subcloned into the pcDNA 3.1/myc-His A vector in frame with a 
C-terminal myc epitope followed by a 6XHis tag (GPR3-pcDNA). All GPR3 mutants were created with a 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) and verified by DNA sequencing. The sequence of full 
length human b-arrestin2 was obtained from a HEK293 cDNA library. Briefly, 1 ug of total RNA was used to 
synthesize the first cDNA strand by means of the Superscript First Strand Synthesis System (Invitrogen) using 
an Oligo(dT) 18 primer. b-arrestin2 (barr2) sequence was amplified by PCR using a High Fidelity Taq DNA 
polymerase (Jena Biosciences) and subcloned into the pEGFP-N1 vector in frame with a C-terminal EGFP tag 
(barr2-pEGFP). The construct was verified by DNA sequencing.
Cell Culture and Transfection. Cell lines were grown in monolayer in Dulbecco’s modified Eagle’s medium 
(DEMEM) supplemented with 10% (v/v) FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine and 
1% (v/v) NEAA (HEK293) or OptiMEM medium supplemented with 10% (v/v) FBS, 200 U/ml penicillin and 
200 μg/ml streptomycin (H4swe) at 37 °C in a moist incubator supplied with 5% CO2 atmosphere. For transfec-
tion, cells were seeded at a density of 15000 cell/well (for 96 well plates) or 45000 cells/well (for 24 well plates) in 
OptiMEM medium supplemented with 10% (v/v) FBS and let to attach overnight. The next day, cells were trans-
fected with the appropriate vectors (50 ng of DNA/well for 96 well plates or 250 ng of DNA/well for 24 well plates) 
using Lipofectamine LTX (ThermoFisher) reagent according to the to manufacturer’s instructions.
Immunostaining and Confocal microscopy analysis. For confocal microscopy, 5 × 10 5 cells/well were 
seeded onto 18 mm round coverslips in a 24-well plate and left to attach overnight. The next day, the medium 
was changed to Optimem supplemented with 10% (v/v) FBS and the cells were transfected with 250 ng of DNA 
as described in the previous section. Twenty four hours after transfection, the cells were washed twice with PBS 
and fixed with 4% paraformaldehyde for 20 min. Fixed cells were treated for 10 min with blocking solution (2% 
BSA, 2% normal goat serum (NGS), 0.2% Triton X100 in PBS) and incubated overnight with anti-myc primary 
antibody (Roche) diluted 1:100 in blocking solution. After three washes with PBS, samples were incubated 
with AlexaFluor-568 goat anti-mouse secondary antibody (ThermoFisher) diluted 1:2000 for 1 hour. After final 
washes, coverslips were treated with a 4′6-diamidino- 2-phenylindole (DAPI) solution (100 ng/mL) for 10 min at 
room temperature. The slips were fixed onto glass slides with a drop of anti-fading mounting medium and sealed 
with nail polish. Images at different Z-planes were collected on a Leica tcs-sp5 confocal microscope. 405 and 
543 nm lasers were used for the excitation of DAPI and Alexafluor dye respectively. Images were processed with 
the software Imaris (Bitplane AG) or ImageJ (ref.1).
cAMP accumulation assay. HEK 293 cells were seeded at a density of 15,000 cells per well in a 96 well plate 
and left to attach overnight. The next day, cells were transfected with 50 ng of plasmidic DNA (pcDNA3.1, WT 
GPR3-pcDNA and mutants, either with or without barr2-pEGFP) as described above. Forty eight hours after 
transfection, cells were incubated with 100 μl of HHBS containing 1 mM IBMX (phosphodiesterase inhibitor) at 
37 °C and for 30 minutes and stimulated with 1 μL of DPI (or forskolin) for additional 30 minutes. DPI and for-
skolin were dissolved in DMSO at different concentrations, according to the experimental design. The medium 
was removed and 50 μl of ice cold 100% ethanol was added to each well. After evaporation, cells were resuspended 
in 50 μl of Lysis buffer (0.3% Tween 20 in HHBS buffer) and incubated at room temperature for 10 minutes. The 
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cAMP concentration in the cell lysate (5 μL) was determined with a cAMP AlphaScreen Assay kit (Perkin Elmer) 
and a EnSpire Alpha Plate Reader (Perkin Elmer) according to the manufacturer’s instructions.
Aβ measurements in H4swe culture medium. H4swe cells were seeded at a density of 15,000 cells per 
well in a 96 well plate and left to attach overnight. The next day, cells were transfected with 50 ng of plasmidic 
DNA (pcDNA3.1, WT GPR3-pcDNA and mutants, either with or without barr2-pEGFP) as described above. 
Twenty four hours after transfection, the medium was replaced with 150 mL of Optimem without serum, either 
in presence or in absence of 1 mM DPI, and the cells were incubated for additional 24 hours at 37 °C. At the end 
of the treatment the concentration of Aβ 1–42 in the culture medium was determined with a commercial ELISA 
kit (Life Technologies).
Statistical analysis. All values shown are the mean +/− SD of three or four independent experiments. 
Statistical significance was determined using one-way ANOVA with Bonferroni-Holmes post-hoc test (multiple 
comparison and comparison of all sets with control).
Data availability. Data generated or analyzed during the current study are available from the corresponding 
author upon request.
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